Symbols / UNCY
UNCY Chart
About
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 142.70M |
| Enterprise Value | 105.65M | Income | -33.41M | Sales | — |
| Book/sh | 1.80 | Cash/sh | 1.99 | Dividend Yield | — |
| Payout | 0.00% | Employees | 22 | IPO | — |
| P/E | — | Forward P/E | 1.14 | PEG | — |
| P/S | — | P/B | 3.69 | P/C | — |
| EV/EBITDA | -3.35 | EV/Sales | — | Quick Ratio | 3.25 |
| Current Ratio | 3.83 | Debt/Eq | 0.71 | LT Debt/Eq | — |
| EPS (ttm) | -3.44 | EPS next Y | 5.85 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 06:00 | ROA | -44.22% |
| ROE | -102.29% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 21.49M |
| Shs Float | 17.90M | Short Float | 7.86% | Short Ratio | 2.52 |
| Short Interest | — | 52W High | 11.00 | 52W Low | 3.71 |
| Beta | 1.84 | Avg Volume | 490.93K | Volume | 329.47K |
| Target Price | $46.50 | Recom | Strong_buy | Prev Close | $6.89 |
| Price | $6.64 | Change | -3.63% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$46.50
Mean price target
2. Current target
$6.71
Latest analyst target
3. DCF / Fair value
$-13.45
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.71
Low
$21.00
High
$90.00
Mean
$46.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-29 | main | HC Wainwright & Co. | Buy → Buy | $22 |
| 2025-09-15 | main | Benchmark | Speculative Buy → Speculative Buy | $21 |
| 2025-04-21 | init | Guggenheim | — → Buy | $6 |
| 2025-04-11 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-04-01 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-01-29 | reit | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-01-08 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-11-22 | reit | Benchmark | Speculative Buy → Speculative Buy | $3 |
| 2024-11-14 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2024-11-12 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-10-09 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-09-06 | reit | Benchmark | Speculative Buy → Speculative Buy | $3 |
| 2024-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-08-15 | main | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-07-10 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-06-25 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-06-03 | reit | Benchmark | Speculative Buy → Speculative Buy | $3 |
| 2024-05-31 | reit | Benchmark | Speculative Buy → Speculative Buy | $3 |
| 2024-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
- FDA sets June 27 action date for Unicycive kidney disease pill - Stock Titan hu, 29 Jan 2026 08
- Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - TMX Newsfile ue, 17 Feb 2026 14
- Retail investors who hold 48% of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 23%, institutions profited as well - Yahoo Finance ue, 18 Nov 2025 08
- Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile - Seeking Alpha hu, 29 Jan 2026 08
- Unicycive Therapeutics Provides Business Update and Financial Results, Poised to Resubmit NDA for Oxylanthanum Carbonate by Year-End | UNCY Stock News - Quiver Quantitative Wed, 12 Nov 2025 08
- Unicycive Therapeutics (NASDAQ:UNCY) Is In A Good Position To Deliver On Growth Plans - simplywall.st Mon, 17 Nov 2025 08
- Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit - GlobeNewswire Wed, 04 Feb 2026 08
- Unicycive Therapeutics Doubles Stock Sale Agreement - TipRanks Fri, 14 Nov 2025 08
- New pill for dialysis patients moves ahead as FDA review restarts - Stock Titan Mon, 29 Dec 2025 08
- When Will Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Turn A Profit? - Yahoo Finance ue, 14 Oct 2025 07
- New Analyst Forecast: $UNCY Given 'Speculative Buy' Rating | UNCY Stock News - Quiver Quantitative Mon, 15 Sep 2025 07
- Unicycive granted FDA review for resubmitted marketing application for kidney disease drug - Seeking Alpha hu, 29 Jan 2026 08
- Unicycive (NASDAQ: UNCY) reports 7x lower pill volume, 2x fewer pills with OLC - Stock Titan Wed, 12 Nov 2025 08
- Is Unicycive Therapeutics (NASDAQ:UNCY) In A Good Position To Invest In Growth? - Yahoo Finance ue, 22 Jul 2025 07
- Unicycive (NASDAQ: UNCY) to present OLC data: 7x lower pill volume, 2x fewer pills at ASN - Stock Titan hu, 30 Oct 2025 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|
| 0 | 652900 | — | — | AGGARWAL GAURAV | Director | — | 2025-08-25 00:00:00 | I |
| 1 | 1400000 | — | — | AGGARWAL GAURAV | Director | — | 2025-02-18 00:00:00 | I |
| 2 | 5500000 | — | — | AGGARWAL GAURAV | Director | — | 2024-10-09 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -30.43M | -19.88M | -17.89M | -8.96M |
| TotalUnusualItems | -5.80M | -10.30M | 0.00 | -412.00K |
| TotalUnusualItemsExcludingGoodwill | -5.80M | -10.30M | 0.00 | -412.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -36.73M | -30.54M | -18.06M | -10.02M |
| ReconciledDepreciation | 428.00K | 284.00K | 161.00K | 13.00K |
| EBITDA | -36.23M | -30.18M | -17.89M | -9.38M |
| EBIT | -36.66M | -30.46M | -18.05M | -9.39M |
| NetInterestIncome | 1.19M | 533.00K | -6.00K | -628.00K |
| InterestExpense | 71.00K | 82.00K | 6.00K | 628.00K |
| InterestIncome | 1.26M | 615.00K | 0.00 | |
| NormalizedIncome | -30.93M | -20.24M | -18.06M | -9.61M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -36.73M | -30.54M | -18.06M | -10.02M |
| TotalExpenses | 32.12M | 21.45M | 19.00M | 8.98M |
| TotalOperatingIncomeAsReported | -32.12M | -20.77M | -18.05M | -8.98M |
| DilutedAverageShares | 6.70M | 2.45M | 1.51M | 1.17M |
| BasicAverageShares | 6.70M | 2.45M | 1.51M | 1.17M |
| DilutedEPS | -5.60 | -12.80 | -12.00 | -8.60 |
| BasicEPS | -5.60 | -12.80 | -12.00 | -8.60 |
| DilutedNIAvailtoComStockholders | -37.82M | -31.41M | -18.06M | -10.02M |
| NetIncomeCommonStockholders | -37.82M | -31.41M | -18.06M | -10.02M |
| PreferredStockDividends | 1.09M | 867.00K | ||
| NetIncome | -36.73M | -30.54M | -18.06M | -10.02M |
| NetIncomeIncludingNoncontrollingInterests | -36.73M | -30.54M | -18.06M | -10.02M |
| NetIncomeContinuousOperations | -36.73M | -30.54M | -18.06M | -10.02M |
| PretaxIncome | -36.73M | -30.54M | -18.06M | -10.02M |
| OtherIncomeExpense | -5.80M | -10.30M | -412.00K | |
| SpecialIncomeCharges | 0.00 | -412.00K | ||
| OtherSpecialCharges | 412.00K | |||
| GainOnSaleOfSecurity | -5.80M | -10.30M | ||
| NetNonOperatingInterestIncomeExpense | 1.19M | 533.00K | -6.00K | -628.00K |
| InterestExpenseNonOperating | 71.00K | 82.00K | 6.00K | 628.00K |
| InterestIncomeNonOperating | 1.26M | 615.00K | 0.00 | |
| OperatingIncome | -32.12M | -20.77M | -18.05M | -8.98M |
| OperatingExpense | 32.12M | 21.45M | 19.00M | 8.98M |
| ResearchAndDevelopment | 20.01M | 12.90M | 12.44M | 6.08M |
| SellingGeneralAndAdministration | 12.10M | 8.55M | 6.57M | 2.90M |
| GeneralAndAdministrativeExpense | 12.10M | 8.55M | 6.57M | 2.90M |
| OtherGandA | 12.10M | 8.55M | 6.57M | 2.90M |
| TotalRevenue | 0.00 | 675.00K | 951.00K | 0.00 |
| OperatingRevenue | 0.00 | 675.00K | 951.00K | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 11.38M | 3.48M | 1.52M | 1.50M |
| ShareIssued | 11.38M | 3.48M | 1.52M | 1.50M |
| TotalDebt | 773.00K | 811.00K | 201.00K | 335.00K |
| TangibleBookValue | 7.43M | -3.81M | -466.00K | 16.48M |
| InvestedCapital | 7.52M | -3.79M | -420.00K | 16.51M |
| WorkingCapital | 6.83M | -4.13M | -640.00K | 16.31M |
| NetTangibleAssets | 7.43M | -3.81M | -466.00K | 16.48M |
| CapitalLeaseObligations | 681.00K | 793.00K | 155.00K | 306.00K |
| CommonStockEquity | 7.43M | -3.81M | -466.00K | 16.48M |
| TotalCapitalization | 7.43M | -3.81M | -466.00K | 16.48M |
| TotalEquityGrossMinorityInterest | 7.43M | -3.81M | -466.00K | 16.48M |
| StockholdersEquity | 7.43M | -3.81M | -466.00K | 16.48M |
| RetainedEarnings | -101.27M | -64.54M | -34.00M | -15.94M |
| AdditionalPaidInCapital | 108.59M | 60.70M | 33.52M | 32.41M |
| CapitalStock | 114.00K | 35.00K | 15.00K | 15.00K |
| CommonStock | 114.00K | 35.00K | 15.00K | 15.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 24.24M | 18.00M | 3.28M | 2.26M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 117.00K | 466.00K | 0.00 | 155.00K |
| LongTermDebtAndCapitalLeaseObligation | 117.00K | 466.00K | 0.00 | 155.00K |
| LongTermCapitalLeaseObligation | 117.00K | 466.00K | 0.00 | 155.00K |
| CurrentLiabilities | 24.12M | 17.53M | 3.28M | 2.10M |
| OtherCurrentLiabilities | 18.94M | 13.13M | ||
| CurrentDebtAndCapitalLeaseObligation | 656.00K | 345.00K | 201.00K | 180.00K |
| CurrentCapitalLeaseObligation | 564.00K | 327.00K | 155.00K | 151.00K |
| CurrentDebt | 92.00K | 18.00K | 46.00K | 29.00K |
| LineOfCredit | 92.00K | 18.00K | 46.00K | 29.00K |
| PayablesAndAccruedExpenses | 4.53M | 4.05M | 3.08M | 1.93M |
| CurrentAccruedExpenses | 3.56M | 3.23M | 2.24M | 1.21M |
| Payables | 966.00K | 821.00K | 846.00K | 713.00K |
| DuetoRelatedPartiesCurrent | 0.00 | |||
| AccountsPayable | 966.00K | 821.00K | 846.00K | 713.00K |
| TotalAssets | 31.67M | 14.19M | 2.82M | 18.74M |
| TotalNonCurrentAssets | 720.00K | 792.00K | 174.00K | 333.00K |
| NetPPE | 720.00K | 792.00K | 174.00K | 333.00K |
| AccumulatedDepreciation | -39.00K | -16.00K | -7.00K | -1.00K |
| GrossPPE | 759.00K | 808.00K | 181.00K | 334.00K |
| Leases | 49.00K | 21.00K | 15.00K | 15.00K |
| ConstructionInProgress | 10.00K | 0.00 | ||
| OtherProperties | 26.00K | 305.00K | ||
| MachineryFurnitureEquipment | 29.00K | 21.00K | 14.00K | 14.00K |
| BuildingsAndImprovements | 645.00K | 766.00K | 152.00K | 305.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 30.95M | 13.40M | 2.64M | 18.41M |
| OtherCurrentAssets | 939.00K | 325.00K | 159.00K | 126.00K |
| CurrentDeferredAssets | 0.00 | |||
| PrepaidAssets | 3.87M | 3.37M | 2.03M | 1.71M |
| CashCashEquivalentsAndShortTermInvestments | 26.14M | 9.70M | 455.00K | 16.58M |
| CashAndCashEquivalents | 26.14M | 9.70M | 455.00K | 16.58M |
| CashFinancial | 26.14M | 9.70M | 455.00K | 16.58M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -28.65M | -18.30M | -15.65M | -5.80M |
| RepaymentOfDebt | 0.00 | -1.36M | ||
| IssuanceOfDebt | 0.00 | 1.35M | ||
| IssuanceOfCapitalStock | 50.68M | 30.19M | 11.00K | 22.27M |
| CapitalExpenditure | -72.00K | -12.00K | -2.00K | -29.00K |
| InterestPaidSupplementalData | 12.00K | 24.00K | 6.00K | |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 26.14M | 9.70M | 455.00K | 16.58M |
| BeginningCashPosition | 9.70M | 455.00K | 16.58M | 0.00 |
| ChangesInCash | 16.44M | 9.25M | -16.12M | 16.58M |
| FinancingCashFlow | 45.09M | 27.54M | -471.00K | 22.38M |
| CashFlowFromContinuingFinancingActivities | 45.09M | 27.54M | -471.00K | 22.38M |
| NetOtherFinancingCharges | -4.50M | -2.65M | -482.00K | |
| ProceedsFromStockOptionExercised | 0.00 | 119.00K | ||
| CashDividendsPaid | -1.09M | 0.00 | ||
| NetPreferredStockIssuance | 50.00M | 30.19M | 0.00 | |
| PreferredStockIssuance | 50.00M | 30.19M | 0.00 | |
| NetCommonStockIssuance | 683.00K | 0.00 | 11.00K | 22.27M |
| CommonStockIssuance | 683.00K | 0.00 | 11.00K | 22.27M |
| NetIssuancePaymentsOfDebt | 0.00 | -15.00K | ||
| NetLongTermDebtIssuance | 0.00 | -15.00K | ||
| LongTermDebtPayments | 0.00 | -1.36M | ||
| LongTermDebtIssuance | 0.00 | 1.35M | ||
| InvestingCashFlow | -72.00K | -12.00K | -2.00K | -29.00K |
| CashFlowFromContinuingInvestingActivities | -72.00K | -12.00K | -2.00K | -29.00K |
| NetPPEPurchaseAndSale | -72.00K | -12.00K | -2.00K | -29.00K |
| PurchaseOfPPE | -72.00K | -12.00K | -2.00K | -29.00K |
| OperatingCashFlow | -28.57M | -18.28M | -15.65M | -5.77M |
| CashFlowFromContinuingOperatingActivities | -28.58M | -18.28M | -15.65M | -5.77M |
| ChangeInWorkingCapital | -427.00K | -93.00K | 1.18M | -105.00K |
| ChangeInOtherCurrentLiabilities | -397.00K | -252.00K | -151.00K | -12.00K |
| ChangeInPayablesAndAccruedExpense | 790.00K | 1.28M | 1.27M | 1.23M |
| ChangeInPayable | 790.00K | 1.28M | 1.27M | 1.23M |
| ChangeInAccountPayable | 790.00K | 1.28M | 1.27M | 1.24M |
| ChangeInPrepaidAssets | -820.00K | -1.12M | 62.00K | -1.32M |
| OtherNonCashItems | 1.00K | 21.00K | 3.25M | |
| StockBasedCompensation | 2.35M | 1.77M | 1.05M | 966.00K |
| DepreciationAmortizationDepletion | 428.00K | 284.00K | 161.00K | 13.00K |
| DepreciationAndAmortization | 428.00K | 284.00K | 161.00K | 13.00K |
| Depreciation | 428.00K | 284.00K | 161.00K | 13.00K |
| OperatingGainsLosses | 5.80M | 10.30M | 127.00K | |
| PensionAndEmployeeBenefitExpense | 0.00 | 146.00K | ||
| GainLossOnInvestmentSecurities | 5.80M | 10.30M | ||
| NetIncomeFromContinuingOperations | -36.73M | -30.54M | -18.06M | -10.02M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for UNCY
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|